Product logins

Find logins to all Clarivate products below.


Dyslipidemia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of dyslipidemia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s dyslipidemia forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dyslipidemia?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of dyslipidemia?
  • How will improvements in survival change the number of people living with a diagnosis of dyslipidemia?
  • Of all people diagnosed with dyslipidemia, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dyslipidemia over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following dyslipidemia subpopulations:

  • Total dyslipidemia prevalent cases.
  • Total dyslipidemia prevalent cases by disease subtype.
  • Primary prevention prevalent cases by disease subtype.
  • Secondary prevention prevalent cases by disease subtype.
  • Total dyslipidemia prevalent cases by diagnosis scheme.
  • Diagnosed prevalent cases by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Endometrial Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Report
Pemphigus Vulgaris – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pemphigus vulgaris patient populations, covering 171 countries and…
Report
Pemphigus Vulgaris – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the…
Report
Pemphigus Vulgaris – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of pemphigus vulgaris (PV) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France…
Report
Gene Therapies for Rare Diseases | Disease Landscape & Forecast | G7 | 2025
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…